Celadon Pharmaceuticals PLC Notice of Results (0161Z)
September 12 2022 - 2:01AM
UK Regulatory
TIDMCEL
RNS Number : 0161Z
Celadon Pharmaceuticals PLC
12 September 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notice of Results and Investor Presentation
LONDON, 12 September 2022: Celadon Pharmaceuticals Plc (AIM:
CEL), a leading UK based pharmaceutical company focused on the
development and supply of natural cannabis-based medicines, will
announce its maiden results for the six months ended 30 June 2022
on Thursday 29 September 2022.
Analyst Briefing: 9.00am, Thursday 29 September 2022
Management will host a virtual analyst presentation followed by
a Q&A session at 9.00am BST on Thursday 29 September 2022.
Analysts wishing to join should register their interest by
contacting celadon@powerscourt-group.com .
Investor Presentation: 2.30pm, Thursday 29 September 2022
Management will be hosting a live presentation and Q&A
session via the online platform, Investor Meet Company, at 2.30pm
BST on Thursday 29 September 2022.
The presentation is open to analysts and all existing and
potential shareholders. Questions can be submitted pre-event via
the Investor Meet Company dashboard up until 9.00am on Thursday 29
September 2022 or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free via:
https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
Investors who already follow Celadon on the Investor Meet
Company platform will automatically receive an invitation to the
event.
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Andrew Potts / Patrick Dolaghan / Bobbie
Hilliam +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0)20 7250 1446
/ celadon@powerscourt-group.com
Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and supply of
natural cannabis-based medicines. Its primary focus is on improving
quality of life for chronic pain sufferers, as well as exploring
the potential of cannabis-based medicines for other conditions such
as autism. Its 100,000 sq. ft UK facility comprises a laboratory
designed to meet GMP standards, and capacity for a large indoor
hydroponic growing facility that has received a Home Office License
to legally grow high-THC medicinal cannabis for the purpose of
producing test batches of cannabis oil to support its application
to the MHRA. The Company's subsidiary, LVL, owns a MHRA
conditionally-approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.
For further information please visit our website
www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBGGDCBBBDGDB
(END) Dow Jones Newswires
September 12, 2022 02:01 ET (06:01 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2024 to Jun 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2023 to Jun 2024